How Much Metformin Do People Take for Weight Loss?

Metformin is not FDA-approved as a weight-loss medication, so there is no official dose for weight loss. In studies and clinical use, providers often start low, such as 500 mg once daily, then adjust gradually if appropriate. Weight loss is usually modest and depends on diagnosis, kidney function, tolerance, diet, and activity 1.

How much metformin do people take to lose weight?

Metformin has no FDA-approved weight-loss dose. When it is used for weight-related reasons, that is usually off-label unless the main reason is type 2 diabetes management. In published studies, weight-related dosing often falls near 1,000–2,000 mg per day, but the right plan depends on the person, not a target number 1, 2.

Why there is no FDA-approved metformin dose for weight loss

Metformin hydrochloride, sold historically under brand names such as Glucophage, Glucophage XR, Fortamet, Glumetza, and Riomet, is approved to improve blood glucose control in people with type 2 diabetes 1. It is not FDA-approved as a stand-alone obesity medication, so the label does not give a weight-loss titration schedule.

Typical starting doses clinicians may consider

The FDA label for immediate-release metformin describes starting at 500 mg twice daily or 850 mg once daily with meals for adults with type 2 diabetes, with gradual increases based on response and tolerance 1. Some clinicians use a lower first step, such as 500 mg once daily, to reduce stomach side effects, but any plan should come from the prescriber.

Why dose increases are gradual

Metformin commonly causes nausea, diarrhea, gas, or abdominal discomfort, especially early in treatment 1. Slow dose changes and taking it with food can help some people tolerate it, but side effects, kidney function, and other risks may limit dose increases.

Is 500 mg of metformin enough to lose weight?

500 mg of metformin may be enough for some people to start, but it is not always the dose used in studies that report weight change. Many trials used higher daily amounts, while some people stay at lower doses because of side effects, kidney function, or a clinician’s risk-benefit judgment 1, 3.

Why 500 mg is often a starting dose, not always a target dose

A low starting dose lets the gut adjust. In diabetes labeling, dose increases are based on glycemic response and tolerability, not weight loss alone 1. For weight-related off-label use, clinicians may use the same cautious idea: start low, monitor, then decide whether a change is appropriate.

Who may respond to lower doses

People with insulin resistance, prediabetes, polycystic ovary syndrome (PCOS), or type 2 diabetes may see weight or appetite changes at different doses because their starting insulin and glucose biology differs 3, 4. A lower dose may also be the safer choice for someone who has more side effects or reduced kidney function.

When clinicians may consider increasing or changing treatment

A clinician may reassess if weight, hemoglobin A1c, fasting glucose, or side effects are not moving in a useful direction. They may also discuss a different medication class, such as a GLP-1 receptor agonist, when the main goal is obesity treatment and the person is eligible 6, 7.

What metformin dosing schedules are commonly used?

Metformin dosing schedules differ by formulation. Immediate-release metformin is often divided across the day with meals, while extended-release metformin is commonly taken once daily with the evening meal in FDA labeling 1.

Immediate-release metformin dosing patterns

The FDA label describes adult immediate-release metformin starting doses of 500 mg twice daily or 850 mg once daily with meals, with increases in 500 mg weekly or 850 mg every two weeks when clinically appropriate 1. The label lists a maximum of 2,550 mg per day for adults with type 2 diabetes, but that is not a weight-loss instruction.

Extended-release metformin dosing patterns

For extended-release metformin, the FDA label describes a usual adult starting dose of 500 mg once daily with the evening meal, with weekly 500 mg increases as needed and tolerated, up to 2,000 mg once daily 1. Extended-release tablets may reduce digestive symptoms for some people, but they are not right for everyone.

Why taking metformin with meals may improve tolerability

Food can make metformin easier on the stomach, which is why the label includes meal-based dosing language 1. If nausea or diarrhea is strong, the answer is not to force the dose higher; it is to message the prescriber.

How much weight can you lose on metformin?

Metformin weight loss is usually modest. In the Diabetes Prevention Program, people assigned to metformin lost an average of about 2.1 kg over 2.8 years, compared with 0.1 kg with placebo and 5.6 kg with intensive lifestyle changes; individual results vary 3.

What clinical studies suggest about average weight change

In the Diabetes Prevention Program, metformin lowered diabetes risk in adults with elevated glucose and overweight or obesity, and it produced modest average weight loss 3. Longer follow-up found that people who stayed on metformin and lost weight early were more likely to maintain some weight loss over time, but the average change remained smaller than what is seen in modern obesity-drug trials 2.

Why 20 pounds is possible for some people but not typical for everyone

Some people may lose 20 pounds if they start at a higher weight, change nutrition and activity, improve insulin resistance, or use other treatments. But metformin alone should not be expected to cause that amount for most people, based on average trial results 2, 3.

How long weight loss may take

Metformin-related weight change tends to be gradual, often over months rather than weeks. That pace fits with its mechanism: it improves liver glucose output and insulin sensitivity rather than directly creating the strong appetite effect seen with GLP-1 medicines 1, 6.

Why lifestyle changes still matter

In the Diabetes Prevention Program, intensive lifestyle change led to greater average weight loss than metformin and reduced progression to diabetes more than metformin 3. Medication can help the biology, but food patterns, protein, sleep, resistance training, and movement still matter.

Who might be prescribed metformin for weight-related reasons?

Metformin may be considered when weight is tied to blood sugar, insulin resistance, PCOS, or certain medications. For people without diabetes, using it mainly for weight loss is off-label, which means the clinician must make an individualized judgment 1.

Type 2 diabetes with overweight or obesity

Metformin is widely used in type 2 diabetes because it lowers glucose without usually causing weight gain 1. For a person with type 2 diabetes and overweight or obesity, weight change may be a secondary benefit, not the labeled reason for treatment.

Prediabetes or insulin resistance

In adults with elevated glucose and overweight or obesity, the Diabetes Prevention Program found that metformin reduced progression to diabetes compared with placebo, while intensive lifestyle change had the largest effect 3. This is one reason clinicians may discuss metformin in prediabetes or insulin resistance.

Polycystic ovary syndrome, or PCOS

PCOS is often linked with insulin resistance. Clinical guidance from the Endocrine Society says metformin may be used in PCOS for type 2 diabetes or impaired glucose tolerance when lifestyle change is not enough, and may help menstrual irregularity, but it is not first-line for obesity alone 4.

Antipsychotic-associated weight gain

Metformin has also been studied for weight gain linked to antipsychotic medicines. In a randomized trial in people with first-episode schizophrenia, metformin plus lifestyle intervention led to greater reductions in weight and insulin resistance than placebo-based approaches, but this use requires careful psychiatric and medical coordination 5.

People without diabetes: what off-label use means

Off-label use is legal when a licensed clinician judges it appropriate, but it is not the same as FDA approval for that use. For metformin and weight loss, the prescriber should explain expected benefits, side effects, kidney monitoring, and alternatives.

What side effects or safety issues can affect the dose?

Metformin safety depends heavily on the gut and the kidneys. The FDA label includes digestive side effects, vitamin B12 monitoring, eGFR-based kidney guidance, and a boxed warning for rare lactic acidosis 1.

Common digestive side effects

Diarrhea, nausea, vomiting, gas, and abdominal discomfort are common reasons people struggle with metformin 1. Taking it with meals or using an extended-release form may help some people, but persistent symptoms should be reviewed.

Vitamin B12 monitoring

The FDA label notes that metformin can lower vitamin B12 levels in some people and recommends periodic blood counts, with B12 measurement in some cases 1. Low B12 can contribute to anemia or nerve symptoms, so monitoring matters during longer use.

Kidney function and eGFR considerations

The label says metformin is contraindicated when eGFR is below 30 mL/min/1.73 m², and starting metformin is not recommended when eGFR is 30 to 45 mL/min/1.73 m² 1. Kidney function also needs review around certain imaging procedures using iodinated contrast.

Lactic acidosis warning

Metformin has a boxed warning for lactic acidosis, a rare but serious buildup of lactate that can be fatal 1. Risk rises with significant kidney impairment, some acute illnesses, heavy alcohol use, liver problems, and low-oxygen states.

Alcohol, pregnancy, and medication interaction considerations

Alcohol can increase lactic acidosis risk with metformin, and pregnancy or fertility goals should be discussed before starting or changing it 1, 4. Other medicines and acute illnesses can also change the safety picture, which is why dose changes should go through a prescriber.

How does metformin compare with GLP-1 weight-loss medications?

Metformin and GLP-1 medicines work in different ways. Metformin mainly lowers liver glucose production and improves insulin sensitivity, while semaglutide and tirzepatide act on gut-hormone pathways that affect appetite, fullness, and glucose regulation 1, 6, 8.

Metformin’s mechanism compared with GLP-1 and GIP medicines

Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist; Mounjaro and Zepbound contain tirzepatide, a dual GIP/GLP-1 receptor agonist. Compounded semaglutide via 503A pharmacy and compounded tirzepatide via 503A pharmacy are prescription compounded formulations, not FDA-approved brand products and not FDA-evaluated for outcomes 6, 8.

Why semaglutide and tirzepatide are usually associated with greater weight loss

In STEP 1, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention and had a mean body-weight change of -14.9% at 68 weeks, compared with -2.4% with placebo; nausea, diarrhea, vomiting, and constipation were common 6. In SURMOUNT-1, tirzepatide 5 mg, 10 mg, or 15 mg once weekly led to mean weight reductions of -15.0%, -19.5%, and -20.9% at 72 weeks, compared with -3.1% with placebo; gastrointestinal side effects were common and discontinuations occurred 8. Individual results vary, and these trial outcomes are not established for compounded formulations.

FDA-approved obesity medications versus off-label diabetes medications

Wegovy and Zepbound have FDA-approved obesity indications in specific eligible groups, while metformin is FDA-approved for type 2 diabetes, not obesity 1, 7, 9. That difference affects labeling, insurance rules, monitoring, and the kind of evidence a clinician uses when discussing options.

Cost, access, tolerability, and clinical fit

Metformin is often low cost, but may not match the weight-loss effect some people seek. GLP-1 and GIP/GLP-1 medicines may be a better clinical fit for some patients with obesity, but they also have side effects, contraindications, access issues, and monitoring needs 6, 8.

Metformin vs GLP-1 treatment at Chia: what options can a clinician review?

Chia does not list metformin as a current treatment. If your main question is whether metformin is right for you, a primary care clinician or endocrinology clinician who can review your labs, eGFR, hemoglobin A1c, and history is the right starting point.

At Chia, our licensed providers evaluate patients online for compounded GLP-1 weight-management options. We offer semaglutide injection, with plans currently starting at $249/month, and tirzepatide tablets or injection, with tablet plans currently starting at $249/month and injection plans currently starting at $299/month. Compounded medications are not FDA-approved.

Microdosing plans are available for semaglutide and tirzepatide when a Chia provider decides they are clinically appropriate. Medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved. Patients can message their care team through the portal between visits.

Some patients also compare GLP-1 care with Chia protocols such as Weight + Energy or Weight + Muscle. If you use an AI agent to manage care tasks, Chia is also reachable through DoctorMCP at mcp.chia.health, which can help route eligible patients toward the online visit process.

What should you ask your clinician before taking metformin for weight loss?

Before taking metformin, ask why it fits your diagnosis and what monitoring you need. The safest plan is based on labs, kidney function, side effects, pregnancy status, and the other medications you take 1.

1. 1Is metformin appropriate for my diagnosis, such as type 2 diabetes, prediabetes, insulin resistance, PCOS, or medication-associated weight gain?
2. 2What labs should be checked before and during treatment, including hemoglobin A1c, kidney function with eGFR, and possibly vitamin B12?
3. 3Which formulation is safest for me: immediate-release metformin or extended-release metformin?
4. 4What side effects should prompt me to message you or schedule a visit?
5. 5Are there reasons I should avoid metformin, such as low eGFR, heavy alcohol use, acute illness, pregnancy considerations, or medication interactions?
6. 6Should I consider other weight-loss treatments, including GLP-1 options, lifestyle treatment, or a higher level of obesity care?

If you are comparing medication paths and want to know whether a Chia option may fit, you can start with the online eligibility quiz. The quiz is not a prescription; it helps our providers decide whether a full clinical review is appropriate.

FAQ

Keep reading

Weight Loss Medication

Metformin Dose for Weight Loss: What the Evidence Actually Shows

Weight Loss Medications

Metformin for Weight Loss: How It Works, How Much to Expect, and Who It’s For

Weight Loss Medications

Metformin Dose for Weight Loss: What the Evidence Actually Shows